

Presenter/Co-Author	Corr. Author	Title	Abstract Number	Session	Date	Time
Makenna May	Maria Amaya	Analysis of CD8 cytotoxic T-cells in patients with myelodysplastic syndrome (MDS) and T-cell large granulocyte lymphocytic leukemia (T-LGLL) reveal a distinct phenotype compared to those with T-LGLL	—	Posters	8-Dec	6-8pm
Elisa Hofmeister	Ajay Major	Health-related quality of life (HRQoL) in real-world patients with cutaneous T cell lymphoma (CTCL): Evaluation of patient reported outcomes using the Skindex-16 in a multidisciplinary CTCL clinic	1866	Posters	6-Dec	5:30-7:30pm
Kunhwa Kim	Ajay Major	Identification of an optimal absolute lymphocyte count before bispecific antibody therapy for large B-cell lymphoma: A collaborative US bispecific consortium study	1967	Posters	6-Dec	5:30-7:30pm
Ajay Major	Ajay Major	Differences in patient-reported time toxicity between bispecific antibody (BsAb) options: Impact of treatment duration and dosing frequency on patient-reported time burden in relapsed/refractory (R/R) follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL)	6181	Posters	8-Dec	6-8pm
Ajay Major	Ajay Major	Comparison of real-world survival outcomes and time toxicity of CAR T-cell versus bispecific antibody therapies in relapsed/refractory follicular lymphoma: A multicenter cohort from 15 US academic institutions	1798	Posters	6-Dec	6-8pm
Manali Kamdar	Manali Kamdar	INSIGHT: A baseline laboratory profile independently predicts outcomes and demonstrates superiority of lisocabtagene maraleucel (liso-cel) over standard of care (SOC) in second-line (2L) large B-cell lymphoma (LBCL) regardless of baseline profile	1775	Posters	6-Dec	5:30-7:30pm

Manali Kamdar	Manali Kamdar	Lisocabtagene maraleucel (liso-cel) versus standard of care (SOC) for second-line relapsed or refractory large B-cell lymphoma (LBCL): First Results from long-term follow-up of TRANSFORM	3710	Posters	7-Dec	6-8pm
Manali Kamdar	Manali Kamdar	Fixed-duration intravenous mosunetuzumab plus polatuzumab vedotin combination therapy continues to demonstrate durable responses in patients with large B-cell lymphoma: 3-year follow-up from a Phase Ib/II study	3735	Posters	7-Dec	6-8pm
Manali Kamdar (co-author)	_	Aggressive Lymphomas: Epidemiological Excluding Prospective Clinical Trials: Real-world data to assess CAR outcomes and frailty	783	626. Aggressive Lymphomas: Epidemiological Excluding Prospective Clinical Trials: Real-world data to assess CAR outcomes and frailty	8-Dec	11-11:15am
Manali Kamdar (co-author)	_	Superior real-world outcomes of lisocabtagene maraleucel in chronic lymphocytic leukemia	798	642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: MRD Guided Therapy and Emergence of Resistance	8-Dec	11:45am-12pm
Manali Kamdar (co-author)	_	Pirtobruitnib in relapsed refractory MCL	5351	Posters	8-Dec	6-8pm
Christine McMahon	Christine McMahon	Defining the clinical characteristics and outcomes of adult patients (pts) with 11q23/KMT2A-rearranged Acute Myeloid Leukemia (AML): An analysis from the MARROW consortium	_	908. Outcomes Research: Myeloid Malignancies: Real-World Outcomes in AML.	6-Dec	2-3:30pm

Christine McMahon	Christine McMahon	Next-generation sequencing (NGS) of DNA isolated from nail specimens and run in parallel with tumor NGS accurately and efficiently detects germline predisposition variants in myeloid malignancies	–	903. Health Services and Quality Improvement: Myeloid Malignancies: Where smarter care begins: technological innovations and quality improvement in myeloid malignancies	8-Dec	4:30-6pm
Christine McMahon	Christine McMahon	RNA fusion sequencing identifies clinically relevant and novel fusions with therapeutic implications in adults with Acute Myeloid Leukemia (AML)	–	Posters	8-Dec	6-8pm
Lisa Chu	Lisa Chu	The phases of hematology-oncology fellowship: A single site qualitative study	–	Posters	7-Dec	6-8pm
Marc Schwartz	Marc Schwartz	Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities	4165	Posters	7-Dec	6-8pm
Sweta Patel	Eric Pietras	Targeting nicotinamide salvage pathway is a unique metabolic vulnerability of high-risk MDS stem cells	232	636. Myelodysplastic Syndromes: Basic and Translational: Innovative Approaches to Target Novel Vulnerabilities in MDS Pathobiology	6-Dec	2-3:30pm
Kady Dennis	Dan Sherbenou	CAR-T cells manufactured after multiple myeloma triplet or quadruplet induction therapy have reduced functionality and an altered composition		Posters	8-Dec	6-8pm
Michael Jones		The impact of monocytic phenotype and NPM1-mutation status in Acute Myeloid Leukemia when treated with traditional induction chemotherapy compared to azacitidine and venetoclax	3478	Posters	7-Dec	6-8pm

Dan Pollyea (co-author)	Curtis Lachoweicz	Prognostic risk integration for survival modeling (PRISM) in newly diagnosed acute myeloid leukemia treated with venetoclax: a multinational retrospective cohort study	453	618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: AML Biomarkers in Action: Prognosis, Risk, and Real-World Insights	7-Dec	10-10:15am
Jason Gilbert	Dan Pollyea	County-level analysis reveals two high-incidence regions and potential environmental contributors to myeloid malignancies in Colorado	2853	Posters	6-Dec	5:30-7:30pm
Dan Peters	Dan Pollyea	Phenotypic shift from primitive to monocytic immunophenotype is unique to patients treated with azacitidine + venetoclax (AZA/VEN) and associated with worse outcomes in AML	3377	Posters	7-Dec	6-8pm

Presenter/Co-Author	Corr. Author	Title	Abstract Number	Session	Date	Time
Craig Forester	Craig Forester	AI-driven platform voyager identifies a novel poison exon and splicing modulator to target specific degradation of STAT1	6113	Poster	8-Dec	6-8pm
Matt Witkowski	Matt Witkowski	Lipid uptake via FATP2 enhances CAR-t therapy resistance in B-cell acute lymphoblastic leukemia		605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Beyond Genomic Resistance: epigenetics, metabolism and more	6-Dec	4-4:15pm
Daniela Ortiz	James DeGregori	Distinct mTOR- and CDK1-regulated translation circuits sustain FLT3-mutated AML survival under therapy		Poster	8-Dec	6-8pm
Bridget Hoag	James DeGregori	U2AF1S34F mutant HSPCs have a fitness advantage in aged and inflamed bone marrow	1395	Poster	6-Dec	5:30-7:30pm

Presenter	Title	Session	Date	Time
Maria Amaya	Mitochondria and Metabolism in Blood Cancer and Normal Hematopoiesis -	Friday Workshop - Moderator	5-Dec	3-6pm
Ajay Major	Panelist discussion	LGBTQIA+ Community	7-Dec	11am-12:30pm
Eric Pietras	Role of the Microenvironment in Leukemogenesis	ASH Presidential Symposium	9-Dec	9:45am -11:15am
Eric Pietras	Workshop on Myeloid Biology -	Friday Workshop - Moderator	5-Dec	3-6pm